Dexamethasone nanomedicines for COVID-19

Twan Lammers^{1

2

3}, Alexandros Marios Sofias⁴, Roy van der Meel⁵, Raymond Schiffelers^{6

7}, Gert Storm^{6

8

9}, Frank Tacke¹⁰, Steffen Koschmieder¹¹, Tim H Brümmendorf¹¹, Fabian Kiessling⁴, Josbert M Metselaar¹²

Affiliations

¹ Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. tlammers@ukaachen.de.
² Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands. tlammers@ukaachen.de.
³ Department of Targeted Therapeutics, University of Twente, Enschede, The Netherlands. tlammers@ukaachen.de.
⁴ Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
⁵ Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands.
⁶ Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands.
⁷ Laboratory of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
⁸ Department of Targeted Therapeutics, University of Twente, Enschede, The Netherlands.
⁹ Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore.
¹⁰ Department of Hepatology and Gastroenterology, Charité University Medicine, Berlin, Germany.
¹¹ Department of Medicine IV (Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation), RWTH Aachen University, Aachen, Germany.
¹² Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. jmetselaar@ukaachen.de.

Twan Lammers et al. Nat Nanotechnol. 2020 Aug.

. 2020 Aug;15(8):622-624.

doi: 10.1038/s41565-020-0752-z.

¹ Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. tlammers@ukaachen.de.
² Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands. tlammers@ukaachen.de.
³ Department of Targeted Therapeutics, University of Twente, Enschede, The Netherlands. tlammers@ukaachen.de.
⁴ Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
⁵ Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands.
⁶ Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands.
⁷ Laboratory of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
⁸ Department of Targeted Therapeutics, University of Twente, Enschede, The Netherlands.
⁹ Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore.
¹⁰ Department of Hepatology and Gastroenterology, Charité University Medicine, Berlin, Germany.
¹¹ Department of Medicine IV (Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation), RWTH Aachen University, Aachen, Germany.
¹² Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. jmetselaar@ukaachen.de.

No abstract available

Figures

1. Results — RECOVERY Trial. [Accessed: 2nd July 2020]; Available at: https://www.recoverytrial.net/results.
1. Horby P, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. 2020 doi: 10.1101/2020.06.22.20137273. 2020.06.22.20137273. - DOI
1. Villar J, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267–276. - PubMed
1. Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020 doi: 10.1038/d41586-020-01824-5. - DOI - PubMed
1. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355–362. - PMC - PubMed